What are the lessons of Lipitor's patent expiry in the US?
This article was originally published in Scrip
Executive Summary
Lipitor’s patent expiry this year is the most anticipated end ever for a branded drug. It is not every year that the most successful drug in pharmaceutical industry history succumbs to generic competition and retires from the commercial limelight. Indeed, it seems like forever since people involved in the pharmaceutical industry, healthcare, medical policy, or you name it have been talking about this expiry.